Express News | BrainStorm Cell Therapeutics Updates On NurOwn Stem Cell Therapy For ALS
BCLI Update - Progress Supports Our 10x Plus Value Range Potential
Express News | Brainstorm Cell Therapeutics Inc Says on July 18, Co Received Mvls Deficiency Notice From the Listing Qualifications Department Staff of Nasdaq
Maxim Group Upgrades Brainstorm Cell Therapeutics(BCLI.US) to Buy Rating, Announces Target Price $2
Optimistic Buy Rating for Brainstorm Cell Therapeutics as NurOwn Advances Into Enhanced Phase 3b ALS Trial
Brainstorm Cell Therptcs Price Target Announced at $2.00/Share by Maxim Group
Express News | Maxim Group Upgrades Brainstorm Cell to Buy, Announces $2 Price Target
Brainstorm Cell Analyst Ratings
Express News | Brainstorm Cell Therapeutics Inc : Maxim Group Raises to Buy From Hold
Express News | Brainstorm Cell Therapeutics to Provide Corporate Mid-Year Update on Nurown Program
Express News | BrainStorm Cell Therapeutics Prices $4.0M Registered Direct Offering Of 11,111,111 Shares At $0.36/Share
Brainstorm Cell Therptcs Entered Into Securities Purchase Agreement With a Single Institutional Investor >BCLI
Express News | Brainstorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
Express News | Brainstorm Cell Therapeutics Inc - Alignment With FDA on Nur Own Cmc Aspects
Express News | Brainstorm Cell Therapeutics Reaches Alignment With FDA on Cmc Aspects of Phase 3B Nurown® Clinical Trial
BrainStorm Appoints Haro Hartounian as COO
BrainStorm Cell Therapeutics: Hartounian's Appointment Effective June 18 >GHDN.BE
Express News | Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.d. as Chief Operating Officer
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
12 Health Care Stocks Moving In Monday's Pre-Market Session